FCRL5 and leukemia: To identify an appropriate target for genomic engineering of FCRL5 CAR-T cells to improve their therapeutic persistence, we evaluated the phenotypic characteristics of CAR-T and endogenous T cells in PCs from leukemia patients who received BCMA CAR-T cell therapy using the GSE151310 single-cell transcriptomic dataset.